Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Angion Biomedica Corp (ANGN) USD0.01

Sell:$10.54 Buy:$10.58 Change: $0.48 (4.36%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.48 (4.36%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.48 (4.36%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Contact details

51 Charles Lindbergh Boulevard
Suite 1200
United States
+1 (415) 6554899

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$318.54 million
Shares in issue:
29.80 million
United States
US dollar

Key personnel

  • Itzhak Goldberg
    Chairman, Chief Scientific Officer
  • Jay Venkatesan
    President, Chief Executive Officer, Director
  • Gregory Curhan
    Interim Chief Financial Officer
  • Jennifer Rhodes
    Senior Vice President, Chief Compliance Officer, General Counsel
  • John Neylan
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.